Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/4628
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Henriksson, M | - |
dc.contributor.author | Epstein, DM | - |
dc.contributor.author | Palmer, SJ | - |
dc.contributor.author | Sculpher, MJ | - |
dc.contributor.author | Clayton, TC | - |
dc.contributor.author | Pocock, SJ | - |
dc.contributor.author | Henderson, RA | - |
dc.contributor.author | Buxton, MJ | - |
dc.contributor.author | Fox, KAA | - |
dc.date.accessioned | 2010-12-06T12:01:02Z | - |
dc.date.available | 2010-12-06T12:01:02Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | Heart 94(6): 717-723, 2008 | en_US |
dc.identifier.issn | 1355-6037 | - |
dc.identifier.uri | http://bura.brunel.ac.uk/handle/2438/4628 | - |
dc.description | The published version of the aritcle can be found at the link below. | en_US |
dc.description.abstract | Background: Evidence suggests that an early interventional strategy for patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) can improve health outcomes but also increase costs when compared with a conservative strategy.Objective: The aim of this study was to assess the cost-effectiveness of an early interventional strategy in different risk groups from a UK health-service perspective.Design: Decision-analytic model based on randomised clinical trial data.Main outcome measures: Costs in UK Sterling at 2003/2004 prices and quality-adjusted life years (QALYs) combined into an incremental cost-effectiveness ratio.Methods: Data from the third Randomised Intervention Trial of unstable Angina (RITA 3) was employed to estimate rates of cardiovascular death and myocardial infarction, costs and health-related quality of life. Cost-effectiveness was estimated over patients' lifetimes within the decision-analytic model.Results: The mean incremental cost per QALY gained for an early interventional strategy was approximately £55000, £22000 and £12000 for patients at low, intermediate and high risk, respectively. The early interventional strategy is approximately 1%, 35% and 95% likely to be cost-effective for patients at low, intermediate and high risk, respectively, at a threshold of £20000 per QALY. The cost-effectiveness of early intervention in low-risk patients is sensitive to assumptions about the duration of the treatment effect.Conclusion: An early interventional strategy in patients presenting with NSTE-ACS is likely to be considered cost-effective for patients at high and intermediate risk, but this is less likely to be the case for patients at low risk. | en_US |
dc.language.iso | en | en_US |
dc.publisher | British Medical Journal | en_US |
dc.relation.ispartof | The Health Economics Research Group | |
dc.title | The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial | en_US |
dc.type | Research Paper | en_US |
dc.identifier.doi | http://dx.doi.org/10.1136/hrt.2007.127340 | - |
Appears in Collections: | Health Economics Research Group (HERG) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fulltext.pdf | 198.27 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.